Literature DB >> 19703370

Altered expression of MRP2, MRP3 and UGT2B1 in the liver affects the disposition of morphine and its glucuronide conjugate in a rat model of cholestasis.

Yoshitaka Hasegawa1, Shuichi Kishimoto, Hirokazu Takahashi, Nobuo Inotsume, Yoshikazu Takeuchi, Shoji Fukushima.   

Abstract

OBJECTIVES: The aim was to investigate the disposition of morphine and morphine-3-glucuronide (M3G) in a rat model of cholestasis induced by bile duct ligation (BDL).
METHODS: Morphine (15 mg/kg) was administered intravenously, and morphine and M3G concentrations in the plasma and urine measured by HPLC. Changes in the mRNA expression of multidrug resistance-associated protein (MRP)2, MRP3 and UDP-glucuronosyltransferase (UGT)2B1 in the liver were estimated using RT-PCR. KEY
FINDINGS: Although the plasma morphine concentrations declined exponentially, the elimination was delayed 3 and 5 days after BDL. Plasma M3G concentrations on day 1 after BDL were similar to those in the untreated control group, but were increased 3 and 5 days after BDL. Expression of MRP3 and UGT2B1 mRNA increased after BDL. The urinary excretion of M3G was increased significantly after BDL.
CONCLUSIONS: Enhanced glucuronidation of morphine and transportation of M3G into the blood increased the plasma M3G concentration in the BDL groups. However, M3G disposition 1 day after BDL was similar to that in the untreated control group because urinary excretion of M3G increased.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19703370     DOI: 10.1211/jpp/61.09.0010

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

Review 1.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

Review 2.  Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-07-03       Impact factor: 4.481

Review 3.  Effect of Liver Disease on Hepatic Transporter Expression and Function.

Authors:  Nilay Thakkar; Jason R Slizgi; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2017-04-30       Impact factor: 3.534

4.  Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.

Authors:  Anika L Dzierlenga; John D Clarke; Tiffanie L Hargraves; Garrett R Ainslie; Todd W Vanderah; Mary F Paine; Nathan J Cherrington
Journal:  J Pharmacol Exp Ther       Date:  2014-12-15       Impact factor: 4.030

5.  Pharmacokinetics of Morphine in Rats with Adjuvant-induced Arthritis.

Authors:  Yoshiaki Kimura; Mika Shibata; Mika Tamada; Noriyuki Ozaki; Kunizo Arai
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

Review 6.  Modulation of Opioid Transport at the Blood-Brain Barrier by Altered ATP-Binding Cassette (ABC) Transporter Expression and Activity.

Authors:  Junzhi Yang; Bianca G Reilly; Thomas P Davis; Patrick T Ronaldson
Journal:  Pharmaceutics       Date:  2018-10-18       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.